Arcturus Therapeutics Holdings Inc. Stock
Equities
ARCT
US03969T1097
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.85 USD | -2.13% | +0.37% | -5.33% |
Financials (USD)
Sales 2024 * | 182M | Sales 2025 * | 229M | Capitalization | 821M |
---|---|---|---|---|---|
Net income 2024 * | -81M | Net income 2025 * | -47M | EV / Sales 2024 * | 2.67 x |
Net cash position 2024 * | 336M | Net cash position 2025 * | - | EV / Sales 2025 * | 3.58 x |
P/E ratio 2024 * |
-10.2
x | P/E ratio 2025 * |
-19.8
x | Employees | 180 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.25% |
Latest transcript on Arcturus Therapeutics Holdings Inc.
1 day | -2.13% | ||
1 week | +0.37% | ||
Current month | +16.74% | ||
1 month | +14.90% | ||
3 months | -15.39% | ||
6 months | +30.12% | ||
Current year | -5.33% |
Managers | Title | Age | Since |
---|---|---|---|
Joseph Payne
CEO | Chief Executive Officer | 52 | 13-02-28 |
Andrew Sassine
DFI | Director of Finance/CFO | 59 | 18-12-31 |
Chief Operating Officer | 45 | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Edward Holmes
BRD | Director/Board Member | 83 | 19-08-31 |
James Barlow
BRD | Director/Board Member | 65 | 18-05-26 |
Peter Farrell
CHM | Chairman | 81 | 18-05-26 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-21 | 29.85 | -2.13% | 244,549 |
24-05-20 | 30.5 | +2.42% | 311,913 |
24-05-17 | 29.78 | -2.36% | 354,617 |
24-05-16 | 30.5 | +5.12% | 347,673 |
24-05-15 | 29.02 | -2.44% | 293,131 |
Delayed Quote Nasdaq, May 21, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.33% | 821M | |
+44.48% | 54.04B | |
+43.57% | 41.96B | |
-0.86% | 41.92B | |
-7.59% | 28.35B | |
+12.30% | 26.35B | |
-21.83% | 19B | |
+7.15% | 13B | |
+29.40% | 12.28B | |
+25.15% | 12.19B |
- Stock Market
- Equities
- ARCT Stock